查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1605803

乳癌液态切片市场，规模，占有率，趋势，产业分析报告:循环生物标记，各用途，各地区 - 市场预测 2025年～2034年

Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report: By Circulating Biomarkers, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast (2025-2034)
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，预计到2034年，全球乳癌液体切片市场规模将达到27,310.2亿美元。该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

由于全球乳癌盛行率不断上升以及对非侵入性诊断工具的需求不断增长，乳癌液体活检市场正在显着增长。液体切片分析血液样本中的循环肿瘤 DNA (ctDNA) 和循环肿瘤细胞 (CTC)。与传统的组织活检相比，它具有多种优势，包括减少患者不适以及即时监测治疗效果的能力。分子生物学和基因组学的进步正在改进液体活检测试，从而可以更早检测和更准确地治疗乳癌，进一步推动市场成长。

医疗保健专业人员和患者对早期癌症检测益处的认识不断提高，推动了对液体活检解决方案的需求。促进癌症筛检的政府措施和研究资助也在推动市场成长方面发挥重要作用。此外，向个人化医疗的转变强调了标靶治疗，使液体活检成为根据患者独特的基因谱为个别患者量身定制治疗的重要工具。

主要生物技术和製药公司的存在以及活跃的研发活动进一步刺激了该领域的创新。随着医疗保健领域的发展以及越来越多的医疗机构采用液体活检技术，液体活检将改善乳癌的诊断和管理并改善患者的治疗效果。所有这些上述因素正在推动乳癌液体活检市场的成长。

乳癌液体切片市场报告亮点

根据循环生物标记物，到2024年，循环游离DNA（cfDNA）部分由于其灵敏度的提高，在乳癌液体活检市场中占据最大的销售占有率。

随着人们对早期癌症诊断重要性的认识不断增强，早期检测/筛检领域预计将在预测期内实现最高的复合年增长率。

2024 年，由于该地区创新诊断技术的采用率很高，北美在乳癌液体活检市场中占据最大占有率。

由于该地区乳癌盛行率不断上升，预计亚太市场在预测期内的复合年增长率最高。

全球主要市场参与者包括Biocept, Inc.，Epic Sciences, Inc.，F． Hoffmann-La Roche Ltd.，Fluxion Biosciences, Inc.，Myriad Genetics, Inc.，NeoGenomics Laboratories，QIAGEN，Sysmex Corporation，The Menarini Group，Thermo Fisher Scientific, Inc.等。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第4章 全球乳癌液态切片市场洞察

  • 市场概述
  • 乳癌液态切片市场动态
    • 促进因素和机会
      • 技术进步推动市场成长
      • 乳癌发生率上升推动市场成长
    • 阻碍因素与课题
      • 高开发成本
  • PESTEL分析
  • 乳癌液态切片市场应用趋势
  • 价值链分析
  • COVID-19影响分析

第5章 全球乳癌液态切片市场:循环生物标记

  • 主要调查结果
  • 简介
  • 循环肿瘤细胞(CTC)
  • 循环脱离DNA(cfDNA)
  • 细胞外小胞(EV)
  • 其他的循环生物标记

第6章 全球乳癌液态切片市场:各用途

  • 主要调查结果
  • 简介
  • 早期发现·筛检
  • 诊断
  • 监视

第7章 全球乳癌液态切片市场:各地区

  • 主要调查结果
  • 简介
    • 乳癌液态切片市场评估:各地区，2020年～2034年
  • 北美
    • 北美:循环生物标记，2020年～2034年
    • 北美:各用途，2020年～2034年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:循环生物标记，2020年～2034年
    • 欧洲:各用途，2020年～2034年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:循环生物标记，2020年～2034年
    • 亚太地区:各用途，2020年～2034年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:循环生物标记，2020年～2034年
    • 中东·非洲:各用途，2020～2034年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲
  • 南美
    • 南美:循环生物标记，2020年～2034年
    • 南美:各用途，2020年～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第8章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第9章 企业简介

  • The Menarini Group
  • NeoGenomics Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN
  • Biocept, Inc.
  • Sysmex Corporation
  • Fluxion Biosciences, Inc.
  • Epic Sciences, Inc.
Product Code: PM5160

The global breast cancer liquid biopsy market size is expected to reach USD 2,731.02 million by 2034, according to a new study by Polaris Market Research. The report "Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report - By Circulating Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers], Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The breast cancer liquid biopsy market is experiencing significant growth due to the increasing prevalence of breast cancer globally and the rising demand for noninvasive diagnostic tools. Liquid biopsy analyzes circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood samples. It offers several advantages over traditional tissue biopsies, including reduced patient discomfort and the ability to monitor treatment response in real time. Advancements in molecular biology and genomics have improved liquid biopsy tests, enabling earlier detection and more precise treatment of breast cancer, further boosting market growth.

The rising awareness among healthcare professionals and patients regarding the benefits of early cancer detection is driving demand for liquid biopsy solutions. Government initiatives promoting cancer screening and research funding also play a crucial role in fostering market growth. In addition, the shift toward personalized medicine is leading to a greater emphasis on targeted therapies, making liquid biopsies an essential tool for tailoring treatments to individual patients based on their unique genetic profiles.

The presence of major biotechnology and pharmaceutical companies, coupled with robust research and development activities, is further stimulating innovation in this sector. As the healthcare landscape evolves and more providers adopt liquid biopsy technology, it improves breast cancer diagnosis and management while enhancing patient outcomes. All these factors mentioned above drive the breast cancer liquid biopsy market growth.

Breast Cancer Liquid Biopsy Market Report Highlights

Based on circulating biomarkers, in 2024, the circulating cell-free DNA (cfDNA) segment accounted for the largest revenue share in the breast cancer liquid biopsy market due to its enhanced sensitivity.

The early detection/screening segment, by application, is expected to register the highest CAGR during the forecast period due to the increasing awareness of the importance of early cancer diagnosis.

In 2024, North America accounted for the largest share of the breast cancer liquid biopsy market due to high adoption rates of innovative diagnostic technologies across the region.

The Asia Pacific market is expected to register the highest CAGR during the forecast period due to an increasing prevalence of breast cancer across the region.

A few global key market players are Biocept, Inc.; Epic Sciences, Inc.; F. Hoffmann - La Roche Ltd.; Fluxion Biosciences, Inc.; Myriad Genetics, Inc.; NeoGenomics Laboratories; QIAGEN; Sysmex Corporation; The Menarini Group; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the breast cancer liquid biopsy market report on the basis of circulating biomarkers, application, and region:

By Circulating Biomarkers Outlook (Revenue - USD Million, 2020-2034)

  • Circulating Tumor Cells (CTCs)
  • Circulating Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers

By Application Outlook (Revenue - USD Million, 2020-2034)

  • Early Detection/Screening
  • Diagnosis
  • Treatment Selection
  • Monitoring

By Regional Outlook (Revenue - USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Breast Cancer Liquid Biopsy Market Insights

  • 4.1. Breast Cancer Liquid Biopsy Market - Market Snapshot
  • 4.2. Breast Cancer Liquid Biopsy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Technological Advancements are Driving the Market Growth
      • 4.2.1.2. Rising Prevalence of Breast Cancer are Driving the Market Growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Development Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Breast Cancer Liquid Biopsy Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • 5.3. Circulating Tumor Cells (CTCs)
    • 5.3.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Tumor Cells (CTCs), by Region, 2020-2034 (USD Million)
  • 5.4. Circulating Cell-free DNA (cfDNA)
    • 5.4.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Cell-free DNA (cfDNA), by Region, 2020-2034 (USD Million)
  • 5.5. Extracellular Vesicles (EVs)
    • 5.5.1. Global Breast Cancer Liquid Biopsy Market, by Extracellular Vesicles (EVs), by Region, 2020-2034 (USD Million)
  • 5.6. Other Circulating Biomarkers
    • 5.6.1. Global Breast Cancer Liquid Biopsy Market, by Other Circulating Biomarkers, by Region, 2020-2034 (USD Million)

6. Global Breast Cancer Liquid Biopsy Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 6.3. Early Detection/Screening
    • 6.3.1. Global Breast Cancer Liquid Biopsy Market, by Early Detection/Screening, by Region, 2020-2034 (USD Million)
  • 6.4. Diagnosis
    • 6.4.1. Global Breast Cancer Liquid Biopsy Market, by Diagnosis, by Region, 2020-2034 (USD Million)
  • 6.5. Monitoring
    • 6.5.1. Global Breast Cancer Liquid Biopsy Market, by Monitoring, by Region, 2020-2034 (USD Million)

7. Global Breast Cancer Liquid Biopsy Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Breast Cancer Liquid Biopsy Market Assessment, By Geography, 2020-2034 (USD Million)
  • 7.3. Breast Cancer Liquid Biopsy Market - North America
    • 7.3.1. North America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.3.2. North America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.3.3. Breast Cancer Liquid Biopsy Market - U.S.
      • 7.3.3.1. U.S.: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.3.3.2. U.S.: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.3.4. Breast Cancer Liquid Biopsy Market - Canada
      • 7.3.4.1. Canada: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.3.4.2. Canada: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 7.4. Breast Cancer Liquid Biopsy Market - Europe
    • 7.4.1. Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.4.2. Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.3. Breast Cancer Liquid Biopsy Market - UK
      • 7.4.3.1. UK: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.3.2. UK: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.4. Breast Cancer Liquid Biopsy Market - France
      • 7.4.4.1. France: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.4.2. France: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.5. Breast Cancer Liquid Biopsy Market - Germany
      • 7.4.5.1. Germany: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.5.2. Germany: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.6. Breast Cancer Liquid Biopsy Market - Italy
      • 7.4.6.1. Italy: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.6.2. Italy: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.7. Breast Cancer Liquid Biopsy Market - Spain
      • 7.4.7.1. Spain: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.7.2. Spain: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.8. Breast Cancer Liquid Biopsy Market - Netherlands
      • 7.4.8.1. Netherlands: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.8.2. Netherlands: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.9. Breast Cancer Liquid Biopsy Market - Russia
      • 7.4.9.1. Russia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.9.2. Russia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.4.10. Breast Cancer Liquid Biopsy Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.4.10.2. Rest of Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 7.5. Breast Cancer Liquid Biopsy Market - Asia Pacific
    • 7.5.1. Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.5.2. Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.3. Breast Cancer Liquid Biopsy Market - China
      • 7.5.3.1. China: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.3.2. China: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.4. Breast Cancer Liquid Biopsy Market - India
      • 7.5.4.1. India: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.4.2. India: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.5. Breast Cancer Liquid Biopsy Market - Malaysia
      • 7.5.5.1. Malaysia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.5.2. Malaysia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.6. Breast Cancer Liquid Biopsy Market - Japan
      • 7.5.6.1. Japan: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.6.2. Japan: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.7. Breast Cancer Liquid Biopsy Market - Indonesia
      • 7.5.7.1. Indonesia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.7.2. Indonesia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.8. Breast Cancer Liquid Biopsy Market - South Korea
      • 7.5.8.1. South Korea: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.8.2. South Korea: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.9. Breast Cancer Liquid Biopsy Market - Australia
      • 7.5.9.1. Australia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.9.2. Australia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.5.10. Breast Cancer Liquid Biopsy Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.5.10.2. Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 7.6. Breast Cancer Liquid Biopsy Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.6.2. Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.3. Breast Cancer Liquid Biopsy Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.3.2. Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.4. Breast Cancer Liquid Biopsy Market - UAE
      • 7.6.4.1. UAE: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.4.2. UAE: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.5. Breast Cancer Liquid Biopsy Market - Israel
      • 7.6.5.1. Israel: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.5.2. Israel: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.6. Breast Cancer Liquid Biopsy Market - South Africa
      • 7.6.6.1. South Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.6.2. South Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.6.7. Breast Cancer Liquid Biopsy Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.6.7.2. Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • 7.7. Breast Cancer Liquid Biopsy Market - Latin America
    • 7.7.1. Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
    • 7.7.2. Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.7.3. Breast Cancer Liquid Biopsy Market - Mexico
      • 7.7.3.1. Mexico: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.7.3.2. Mexico: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.7.4. Breast Cancer Liquid Biopsy Market - Brazil
      • 7.7.4.1. Brazil: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.7.4.2. Brazil: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.7.5. Breast Cancer Liquid Biopsy Market - Argentina
      • 7.7.5.1. Argentina: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.7.5.2. Argentina: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
    • 7.7.6. Breast Cancer Liquid Biopsy Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
      • 7.7.6.2. Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. The Menarini Group
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. NeoGenomics Laboratories
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. F. Hoffmann - La Roche Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Myriad Genetics, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Thermo Fisher Scientific, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. QIAGEN
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Biocept, Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Sysmex Corporation
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Fluxion Biosciences, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Epic Sciences, Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development

List of Tables:

  • Table 1 Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 2 Global Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 3 North America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 4 North America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 5 U.S.: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 6 U.S.: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 7 Canada: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 8 Canada: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 9 Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 10 Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 11 UK: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 12 UK: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 13 France: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 14 France: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 15 Germany: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 16 Germany: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 17 Italy: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 18 Italy: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 19 Spain: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 20 Spain: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 21 Netherlands: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 22 Netherlands: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 23 Russia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 24 Russia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 25 Rest of Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 26 Rest of Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 27 Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 28 Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 29 China: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 30 China: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 31 India: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 32 India: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 33 Malaysia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 34 Malaysia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 35 Japan: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 36 Japan: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 37 Indonesia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 38 Indonesia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 39 South Korea: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 40 South Korea: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 41 Australia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 42 Australia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 43 Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 44 Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 45 Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 46 Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 47 Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 48 Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 49 UAE: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 50 UAE: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 51 Israel: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 52 Israel: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 53 South Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 54 South Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 55 Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 56 Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 57 Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 58 Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 59 Mexico: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 60 Mexico: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 61 Brazil: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 62 Brazil: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 63 Argentina: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 64 Argentina: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • Table 65 Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  • Table 66 Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
  • List of Figures:
  • Figure 1. Global Breast Cancer Liquid Biopsy Market, 2020-2034 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Circulating Biomarkers
  • Figure 7. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2024 & 2034 (USD Million)
  • Figure 8. Market by Application
  • Figure 9. Global Breast Cancer Liquid Biopsy Market, by Application, 2024 & 2034 (USD Million)